Dupont Capital Management Corp grew its position in shares of Celgene Co. (NASDAQ:CELG) by 12.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,134 shares of the biopharmaceutical company’s stock after purchasing an additional 23,307 shares during the period. Dupont Capital Management Corp’s holdings in Celgene were worth $18,268,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of CELG. Ayalon Holdings Ltd. bought a new position in shares of Celgene in the 2nd quarter valued at about $100,000. Atlantic Trust LLC bought a new position in shares of Celgene in the 2nd quarter valued at about $101,000. Acropolis Investment Management LLC bought a new position in shares of Celgene in the 2nd quarter valued at about $112,000. Moneta Group Investment Advisors LLC lifted its holdings in shares of Celgene by 2,688.6% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 9,921 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Celgene in the 3rd quarter valued at about $132,000. Hedge funds and other institutional investors own 73.58% of the company’s stock.
Shares of NASDAQ CELG opened at $74.02 on Friday. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. The stock has a market capitalization of $52.77 billion, a price-to-earnings ratio of 10.82, a PEG ratio of 0.47 and a beta of 1.53. Celgene Co. has a 1 year low of $70.09 and a 1 year high of $110.81.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.02 by $0.27. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%. On average, sell-side analysts predict that Celgene Co. will post 7.45 earnings per share for the current fiscal year.
CELG has been the subject of a number of analyst reports. Morgan Stanley increased their price target on shares of Celgene from $90.00 to $91.00 and gave the company an “equal weight” rating in a report on Friday, July 13th. Zacks Investment Research downgraded shares of Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. SunTrust Banks reaffirmed a “hold” rating and issued a $101.00 price target on shares of Celgene in a report on Friday, July 27th. Mizuho reaffirmed a “buy” rating and issued a $129.00 price target on shares of Celgene in a report on Tuesday, July 31st. Finally, BidaskClub raised shares of Celgene from a “hold” rating to a “buy” rating in a report on Thursday, August 16th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene has an average rating of “Buy” and a consensus price target of $117.91.
TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/celgene-co-celg-shares-bought-by-dupont-capital-management-corp.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Determine Your Level of Risk Tolerance
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.